Malignant neoplasm of thyroid gland
In Malignant neoplasms of thyroid and other endocrine glands (C73-C75), chapter 2: Neoplasms
- C73 is billable and valid on claims for FY 2027. If the record has more detail, check the other codes under C73-C75 below.
- As a secondary diagnosis it is not a CC or MCC, so it doesn't raise the MS-DRG payment.
- Counts toward HCC 23 (Prostate, Breast, and Other Cancers and Tumors) in the Medicare Advantage risk model (CMS-HCC V28).
- AHRQ's Chronic Condition Indicator classes it as chronic: expected to last 12 months or longer and to limit daily life or need ongoing care.
- 2,229 US deaths in 2024 had an underlying cause in category C73, per the National Vital Statistics System on CDC WONDER. Death records use WHO ICD-10, so the count is for the whole category.
Also indexed as: Adenocarcinoma, follicular, with papillary; Adenocarcinoma, follicular, moderately differentiated; Adenocarcinoma, follicular, trabecular; Adenocarcinoma, follicular, unspecified site; Adenocarcinoma, follicular, well differentiated; Adenocarcinoma, Hurthle cell; Adenocarcinoma, nonencapsulated sclerosing; Adenocarcinoma, papillary, with follicular; Adenocarcinoma, papillary, follicular variant; Carcinoma, C cell, unspecified site; Carcinoma, follicular, with papillary; Carcinoma, follicular, moderately differentiated; Carcinoma, follicular, pure follicle; Carcinoma, follicular, trabecular; Carcinoma, follicular, unspecified site; Carcinoma, follicular, well differentiated; Carcinoma, Hurthle cell; Carcinoma, medullary, with, amyloid stroma, unspecified site; Carcinoma, nonencapsulated sclerosing; Carcinoma, papillary, with follicular; Carcinoma, papillary, follicular variant; Carcinoma, parafollicular cell, unspecified site; Carcinoma, solid, with amyloid stroma, unspecified site; Goiter, cancerous; Goiter, malignant; Hurthle cell, adenocarcinoma; Hurthle cell, carcinoma; Tumor, Hurthle cell, malignant; Tumor, nonencapsulated sclerosing; Wuchernde Struma Langhans
Advertisements
Instructional notes
Use additional code: add a second code for this, listed after this one
- code to identify any functional activity
Official coding guidelines
From the ICD-10-CM Official Guidelines for Coding and Reporting, FY 2027 (CMS and NCHS). Links open the PDF at the right page.
Rules for coding benign and malignant neoplasms: using the Neoplasm Table, sequencing primary and secondary sites, treatment encounters, complications, and current cancer versus personal history.
- Admission/Encounter for treatment of primary site (page 33)
- Admission/Encounter for treatment of secondary site (page 33)
- Coding and sequencing of complications (page 34)
- Primary malignancy previously excised (page 34)
- Admissions/Encounters involving antineoplastic chemotherapy, immunotherapy and radiation therapy (page 35)
- Admission/encounter to determine extent of malignancy (page 36)
- Symptoms, signs, and abnormal findings listed in Chapter 18 associated with neoplasms (page 36)
- Admission/encounter for pain control/management (page 36)
Other codes under C73-C75
Malignant neoplasms of thyroid and other endocrine glands (C73-C75)
- C73Malignant neoplasm of thyroid gland(this code)
- C74Malignant neoplasm of adrenal gland
- C75Malignant neoplasm of other endocrine glands and related structures
C73 MS-DRGs
This code does not group to an MS-DRG as a principal diagnosis.
Related conditions
Grouped by AHRQ's Clinical Classifications Software Refined (CCSR), which sorts every diagnosis code into clinically meaningful categories.
Medicare coverage articles listing C73
These 36 Medicare billing and coding articles list C73 as a diagnosis that supports medical necessity for the services they cover. From the CMS Medicare Coverage Database; check your own contractor's article before billing.
- MolDX: Genetic Testing for Hereditary Thrombophilia (4 contractors)
- MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer (4 contractors)
- MolDX: Minimal Residual Disease Testing for Solid Tumor Cancers (4 contractors)
- MolDX: Next-Generation Sequencing for Solid Tumors (4 contractors)
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Targeted Therapy in Cancer (4 contractors)
- MolDX: Plasma-Based Genomic Profiling in Solid Tumors (4 contractors)
- MolDX: bioTheranostics Cancer TYPE ID® Update (3 contractors)
- Erythropoiesis Stimulating Agents (2 contractors)
- Intraoperative Neurophysiological Testing (2 contractors)
- Lab: Flow Cytometry (2 contractors)
And 26 more.
Other codes that refer to C73
Notes on these codes point to C73.
About the condition
Plain-language background from MedlinePlus (National Library of Medicine), not coding guidance.
Thyroid Cancer
Thyroid cancer is a cancer that starts in the tissues of the thyroid. Your thyroid is a small, butterfly-shaped gland in the front of your neck. It makes hormones that control the way the body uses energy. These hormones affect nearly every organ in your body and control many of your body's most important functions. For example, they affect your breathing, heart rate, weight, digestion, and moods.
Read more about thyroid cancer on MedlinePlusCode history
Valid since FY2016, when ICD-10-CM took effect on October 1, 2015. No changes since.
ICD-9-CM equivalent
Legacy crosswalk from the CMS General Equivalence Mappings (last updated 2018).
- 193 Malignant neoplasm of thyroid gland